Sinovac Biotech

40.031°N 116.3003°E / 40.031; 116.3003

Sinovac Biotech
TypePublic
Nasdaq: SVA
Founded1999 (1999)
FounderYin Weidong[1]
Headquarters39 Shang Di West Road, Haidian District,
Beijing
,
China
Number of employees
4,281 (as of 2022)[2]
Chinese name
Simplified Chinese科兴控股生物技术有限公司
Traditional Chinese科興控股生物技術有限公司
Literal meaningKexing Holdings Biotechnology Co., Ltd.
Websitewww.sinovac.com
This article is about the pharmaceutical company. For the COVID-19 vaccine that it developed, see CoronaVac.
"Sinovac" redirects here. Not to be confused with Sinopharm (company).

Sinovac Biotech Ltd. (Chinese: 科兴控股生物技术有限公司) is a Chinese biopharmaceutical company based in Haidian District, Beijing that focuses on the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. The company was listed on the Nasdaq but the exchange halted Sinovac's trading in February 2019 due to a proxy fight.[3][4] The company has faced bribery probes in China.[3]

Vaccines

Sinovac's commercialized vaccines include CoronaVac (COVID-19 vaccine), Inlive (Enterovirus 71 vaccine), Anflu (influenza vaccine), Healive (hepatitis A vaccine), varicella vaccine and mumps vaccine.[5]

COVID-19 vaccine development
Main article: CoronaVac

CoronaVac is an inactivated virus COVID-19 vaccine developed by Sinovac.[6] It has been in Phase III clinical trials in Brazil,[7] Chile,[8] Indonesia,[9] Philippines,[10] and Turkey.[11]

It relies on traditional technology similar to the Sinopharm BIBP vaccine and Covaxin, otherwise known as inactivated-virus COVID-19 vaccines in Phase III trials.[12] CoronaVac does not need to be frozen, and both the vaccine and raw material for formulating the new doses could be transported and refrigerated at 2–8 °C (36–46 °F), temperatures at which flu vaccines are kept.[13]

A real-world study of ten millions of Chileans who received CoronaVac found it 66% effective against symptomatic COVID-19, 88% against hospitalization, 90% against ICU admissions, and 86% against deaths.[14] In Brazil, after 75% of the population in Serrana, São Paulo received CoronaVac, preliminary results show deaths fell by 95%, hospitalizations by 86%, and symptomatic cases by 80%.[15][16] In Indonesia, real world data from 128,290 healthcare workers showed 94% protection against symptomatic infection by the vaccine, beating results in clinical trials.[17]

Phase III results from Turkey published in The Lancet showed an efficacy of 84% based on 10,218 participants in the trials.[18][19] Phase III results from Brazil previously showed 50.7% efficacy at preventing symptomatic infections and 83.7% effective in preventing mild cases needing treatment. Efficacy against symptomatic infections increased to 62.3% with an interval of 21 days or more between the doses.[20]

CoronaVac is being used in vaccination campaigns in various countries in Asia,[21][22][23] South America,[24][25][26] North America,[27][28][29] and Europe.[30][31][32] By April 2021, Sinovac had a production capacity of two billion doses a year[33] and had delivered 600 million total doses.[34] It is currently being manufactured at several facilities in China,[33] Brazil,[35] and Egypt.[36] On 1 June 2021, the World Health Organization (WHO) validated the vaccine for emergency use.[37][38][39] Sinovac has signed purchase agreements for 380 million doses from COVAX.[40]

See also

References
  1. "China's Vaccine Front-Runner Aims to Beat Covid the Old-Fashioned Way". Bloomberg. 24 August 2020.
  2. Submission Proof - tv479639
  3. Dou, Eva (December 4, 2020). "As China nears a coronavirus vaccine, bribery cloud hangs over drugmaker Sinovac". The Washington Post. ISSN 0190-8286. Archived from the original on December 4, 2020. Retrieved 2020-12-06.
  4. Levine, Matt (May 22, 2020). "A Vaccine With a Poison Pill". Bloomberg News. Archived from the original on June 21, 2020. Retrieved December 6, 2020.
  5. "Vaccines". sinovac.com. Archived from the original on 26 September 2021. Retrieved 1 September 2021.
  6. Nidhi Parekh (22 July 2020). "CoronaVac: A COVID-19 Vaccine Made From Inactivated SARS-CoV-2 Virus". Retrieved 25 July 2020.
  7. "New coronavirus vaccine trials start in Brazil". AP News. 21 July 2020. Retrieved 2020-10-07.
  8. "Chile initiates clinical study for COVID-19 vaccine". Chile Reports. 4 August 2020. Retrieved 2020-10-07.
  9. "248 volunteers have received Sinovac vaccine injections in Bandung". Antara News. 30 August 2020. Retrieved 2020-10-07.
  10. "DOH eyes 5 hospitals for Sinovac vaccine Phase 3 clinical trial". PTV News. 16 September 2020. Retrieved 2020-10-07.
  11. "Turkey begins phase three trials of Chinese Covid-19 vaccine". TRT World News. 1 September 2020. Retrieved 2020-10-07.
  12. Zimmer, Carl; Corum, Jonathan; Wee, Sui-Lee (10 June 2020). "Coronavirus Vaccine Tracker". The New York Times. ISSN 0362-4331. Retrieved 2021-02-12.
  13. "CoronaVac: Doses will come from China on nine flights and can..." AlKhaleej Today (in Arabic). 2020-11-01. Retrieved 2021-02-12.
  14. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. (July 2021). "Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile". The New England Journal of Medicine. 385 (10): 875–884. doi:10.1056/NEJMoa2107715. PMC 8279092. PMID 34233097. S2CID 235766915.
  15. Savarese M (2021-06-01). "Sinovac vaccine restores a Brazilian city to near normal". CTV News. Retrieved 2021-06-02.
  16. Pearson S (2021-05-31). "Brazil's Experiment to Vaccinate Town With Chinese CoronaVac Reduced Covid-19 Deaths by 95%". The Wall Street Journal. ISSN 0099-9660. Retrieved 2021-06-02.
  17. "China Sinovac Shot Seen Highly Effective in Real World Study". Bloomberg News. 3 June 2023. Retrieved 3 June 2023.
  18. Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. (8 July 2021). "Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey". The Lancet. 398 (10296): 213–222. doi:10.1016/S0140-6736(21)01429-X. ISSN 0140-6736. PMC 8266301. PMID 34246358. S2CID 235770533.
  19. Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine (PDF) (Presentation). World Health Organization. 29 April 2021. Retrieved 10 July 2021.
  20. Costa A (2021-04-11). "Estudo clínico que comprova maior eficácia da Coronavac é enviado para Lancet" [Clinical study proving greater efficacy of Coronavac is submitted to The Lancet]. CNN Brasil (in Portuguese). São Paulo. Retrieved 2021-04-12.
  21. TARIGAN, EDNA; MILKO, VICTORIA (13 January 2021). "Indonesia starts mass COVID vaccinations over vast territory". Associated Press. Retrieved 15 January 2021.
  22. "Thailand Kicks Off Covid-19 Vaccine Program With Sinovac Shots". Bloomberg.com. Retrieved 28 February 2021.
  23. "China approves Sinovac vaccines for general public use". South China Morning Post. 6 February 2021. Retrieved 6 February 2021.
  24. Rochabrun, Marcelo. "Brazil health ministry says plans to order 30 million more Coronavac doses | The Chronicle Herald". www.thechronicleherald.ca. Retrieved 26 February 2021.
  25. Miranda, Natalia A. Ramos (28 January 2021). "Chile receives two million-dose first delivery of Sinovac COVID-19 vaccine". Reuters. Retrieved 30 January 2021.
  26. "BNamericas - Uruguay prepares to launch COVID-19 vaccinat..." BNamericas.com. Retrieved 1 March 2021.
  27. "Venustiano Carranza next up for Covid vaccination in Mexico City". Mexico News Daily. 2021-03-15. Retrieved 2021-03-16.
  28. "Anticovid vaccines run out as Dominican Republic awaits arrival of more doses". Dominican Today. Retrieved 2021-03-10.
  29. "Llegan a El Salvador un millón de dosis de la vacuna china CoronaVac contra el covid-19 de la farmacéutica Sinovac". Noticias de El Salvador - La Prensa Gráfica | Informate con la verdad (in European Spanish). Retrieved 2021-03-28.
  30. "Turkey aims to vaccinate 60 percent of population: Minister – Turkey News". Hürriyet Daily News. 11 February 2021. Retrieved 12 February 2021.
  31. "Vaccination with CoronaVac launched in Ukraine on April 13 – Health minister". www.unian.info. Retrieved 2021-04-15.
  32. Semini, Llazar. "Albania starts mass COVID vaccinations before tourist season". ABC News. Retrieved 2021-03-28.
  33. Liu, Roxanne (2021-04-02). "China Sinovac says it reached two billion doses annual capacity for COVID-19 vaccine". Reuters. Retrieved 2021-04-02.
  34. Nebehay, Stephanie (2021-06-01). "WHO approves Sinovac COVID vaccine, the second Chinese-made dose listed". Reuters. Geneva. Retrieved 2021-06-01.
  35. Mano A, Simões (10 December 2020). "Chinese vaccine draws demand across Latin America, say Brazilian officials". Reuters. Archived from the original on 10 December 2020. Retrieved 10 December 2020.
  36. "Egypt to produce up to 80 million Sinovac vaccine doses annually". Arab News. 2021-04-08. Retrieved 2021-04-08.
  37. Nebehay S (2021-06-01). "WHO approves Sinovac COVID vaccine, the second Chinese-made dose listed". Reuters. Geneva. Retrieved 2021-06-01.
  38. "WHO recommendation Sinovac COVID-19 vaccine (Vero Cell [Inactivated]) – CoronaVac". World Health Organization (WHO). 1 May 2021. Archived from the original on 2 June 2021. Retrieved 1 June 2021.
  39. "WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations". World Health Organization (WHO) (Press release). Retrieved 1 June 2021.
  40. "Chinese drugmakers agree to supply more than half a billion vaccines to COVAX". Reuters. 2021-07-12. Retrieved 2021-07-13.
  • Official website Edit this at Wikidata
  • Business data for Sinovac Biotech:
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.